Alterations in Gene Expression and DNA Methylation during Murine and Human Lung Alveolar Septation

Alain Cuna¹, Brian Halloran², Ona Faye-Petersen², David Kelly², David K. Crossman², Xiangqin Cui², Kusum Pandit³, Naftali Kaminski⁴, Soumyaroop Bhattacharya⁵, Ausaf Ahmad⁵, Thomas J. Mariani⁵, and Namasivayam Ambalavanan²

¹University of Missouri–Kansas City, Kansas City, Missouri; ²University of Alabama at Birmingham, Birmingham, Alabama; ³University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania; ⁴Yale School of Medicine, New Haven, Connecticut; and ⁵University of Rochester Medical Center, Rochester, New York

Abstract

DNA methylation, a major epigenetic mechanism, may regulate coordinated expression of multiple genes at specific time points during alveolar septation in lung development. The objective of this study was to identify genes regulated by methylation during normal septation in mice and during disordered septation in bronchopulmonary dysplasia. In mice, newborn lungs (preseptation) and adult lungs (postseptation) were evaluated by microarray analysis of gene expression and immunoprecipitation of methylated DNA followed by sequencing (MeDIP-Seq). In humans, microarray gene expression data were integrated with genome-wide DNA methylation data from bronchopulmonary dysplasia versus preterm and term lung. Genes with reciprocal changes in expression and methylation, suggesting regulation by DNA methylation, were identified. In mice, 95 genes with inverse correlation between expression and methylation during normal septation were identified. In addition to genes known to be important in lung development (Wnt signaling, Angpt2, Sox9, etc.) and its extracellular matrix (Tnc, Eln, etc.), genes involved with immune and antioxidant defense (Stat4, Sod3, Prdx6, etc.) were also observed. In humans, 23 genes were differentially methylated with reciprocal changes in expression in bronchopulmonary dysplasia compared with preterm or term lung. Genes of interest included

those involved with detoxifying enzymes (*Gstm3*) and transforming growth factor- β signaling (bone morphogenetic protein 7 [*Bmp7*]). In terms of overlap, 20 genes and three pathways methylated during mouse lung development also demonstrated changes in methylation between preterm and term human lung. Changes in methylation correspond to altered expression of a number of genes associated with lung development, suggesting that DNA methylation of these genes may regulate normal and abnormal alveolar septation.

Keywords: lung development; premature infant; epigenetics; bronchopulmonary dysplasia

Clinical Relevance

DNA methylation is an important regulator of gene expression. Coordinated expression of multiple genes occurs at specific time points during alveolar septation in lung development. In this study, we identified multiple genes that are potentially regulated by DNA methylation during normal alveolar septation in the mouse and human lung, and in bronchopulmonary dysplasia compared to preterm or term lung.

(Received in original form April 18, 2014; accepted in final form November 10, 2014)

This work was supported by National Institutes of Health grants R01 HL092906 (N.A.), U01 HL122626 (N.A. and N.K.), and R01 HL095397 (N.K.).

Author Contributions: A.C. and N.A.—conceptualized and designed the study, drafted the initial manuscript, revised the manuscript, and approved the final manuscript as submitted; B.H., D.K.C., X.C., K.P., S.B., A.A., and T.J.M.—assisted with the study design, acquisition of data, performed statistical analysis of the data, revised the manuscript, and approved the final manuscript as submitted; N.K., O.F.-P., and D.K.—assisted with the study design, critically reviewed the manuscript, and approved the final manuscript as submitted; N.K., O.F.-P., and D.K.—assisted with the study design, critically reviewed the manuscript, and approved the final manuscript as submitted.

Correspondence and requests for reprints should be addressed to Namasivayam Ambalavanan, M.D., Division of Neonatology, Department of Pediatrics, University of Alabama at Birmingham, 176F Suite 9380, Women and Infants Center, 619 S 19th Street, Birmingham, AL 35249. E-mail: nambalavanan@peds.uab.edu

This article has an online supplement, which is accessible from this issue's table of contents at www.atsjournals.org

Am J Respir Cell Mol Biol Vol 53, Iss 1, pp 60-73, Jul 2015

Copyright © 2015 by the American Thoracic Society

Originally Published in Press as DOI: 10.1165/rcmb.2014-0160OC on November 11, 2014 Internet address: www.atsjournals.org

ORIGINAL RESEARCH

Lung development is a critically important biological process that is highly complex and is divided into five stages-embryonic, pseudoglandular, canalicular, saccular, and alveolar (1). Precise regulation of gene expression is important for normal lung development to occur, and interruptions during key periods in its development can have serious consequences. Preterm infants are especially at risk, as they are born with immature lungs in the saccular stage, and are exposed to a multitude of environmental stressors that can disrupt the transition to the alveolar stage, leading to a form of chronic lung disease, known as bronchopulmonary dysplasia (BPD), characterized by inhibition of alveolar septation and varying degrees of fibrosis and vascular remodeling (2).

The exact molecular mechanisms that govern normal lung development and its arrest in BPD remain unknown (3). Previous studies have used microarray analysis to report gene expression profiles in normal lung development from murine (4) as well as human tissue samples (5). A recent study by Bhattacharya and colleagues (6) has also provided data on gene expression patterns observed in human BPD versus control lung tissue samples. However, despite the wealth of gene expression data from these studies, there are few studies that look at the underlying molecular mechanisms that regulate and maintain the changes in gene expression observed in normal and altered lung development.

DNA methylation is one of the most extensively studied epigenetic mechanisms that regulate gene expression. It is well established that changes in DNA methylation and differences in gene regulation are causally related, with hypomethylation generally leading to gene expression, and hypermethylation resulting in gene silencing (7). DNA methylation is known to be important in a number of biological processes, including normal differentiation and development of tissues and organs (8). Recent studies have demonstrated the significance of DNA methylation in regulating development of various organ systems, including the brain (9), bone (10), prostate (11), and hematopoietic system (12). It is likely that DNA methylation plays an important role in both normal and abnormal lung development.

The purpose of this study was to identify genes likely regulated by DNA

methylation during normal alveolar septation in mice, and during disordered alveolar septation in human BPD. We performed an integrative analysis of both genome-wide DNA methylation and gene expression data, and focused on genes with inverse changes in expression and methylation to highlight genes, the expression of which is likely regulated by DNA methylation. We limited our study to alveolar septation, as BPD is a disease characterized by an arrest in alveolar development.

Materials and Methods

See the online supplement for details.

Lung Tissue Samples

Mouse. C57BL/6 mouse lungs were isolated at Postnatal Day 3 (P3) and at 6 weeks of age (P42) to allow comparison between newborn lungs before initiation and adult lungs after full completion of alveolar septation (13). The protocol was approved by the Institutional Animal Care and Use Committee at the University of Alabama at Birmingham (UAB).

Human. Formalin-fixed, paraffinembedded (FFPE), deidentified autopsy lung tissue samples were obtained after Institutional Review Board approval. The study group consisted of preterm infants with BPD (postmenstrual age, 28–42 wk; n = 6). For comparison, preterm stillbirths (24- to 26-wk gestation; n = 5) and term stillbirths (36–40 wk; n = 6) were used as control groups.

DNA Isolation and DNA Methylation Profiling

Mouse. Mouse genomic DNA was extracted, and methylated DNA fragments were immunoprecipitated using a monoclonal antibody specific to 5methylcytosine (anti–5-methylcytosine, MABE146; Millipore). High-throughput sequencing was then performed using the enriched methylated fragments (MeDIP-Seq) (14).

Human. Genomic DNA was isolated using the QIAmp FFPE Tissue Kit (Qiagen, Valencia, CA) and methylation profile assayed using the Illumina HumanMethylation450 DNA Analysis BeadChip (Illumina).

RNA Isolation and Gene Expression Profiling

Mouse. Total RNA was isolated using the QiagenRNeasy Mini kit (Qiagen) and then profiled using the Agilent Whole-Mouse Genome Microarrays Kit (G4122F; Agilent).

Human. RNA isolated using Qiagen RNeasy FFPE kit (Qiagen) was used for validation of selected genes by real-time RT-PCR (n = 4/group).

Data Analyses

DNA methylation data. MOUSE. MeDIP-Seq data were mapped to the mouse reference genome using Bowtie 2 (http://bowtie-bio. sourceforge.net/bowtie2/). The Model-based Analysis of MeDIP-Seq software program (http://liulab.dfci.harvard.edu/MACS/) identified peak regions with *P* less than 0.05.

HUMAN. HumanMethylation450 data were analyzed using the "minfi" package in Bioconductor (http://www.bioconductor.org/ packages/release/bioc/html/minfi.html). Data were normalized using the subset-quantile within array normalization (15). F-test compared the three groups, and *t* tests were used for pair-wise contrasts to identify differential methylation at each cytosine-phosphateguanine dinucleotide (CpG) site based on M values (logit transformation of β values). False discovery rate (FDR) of less than 0.05 was used to select significant CpG sites in BPD compared with preterm and term groups (16).

Gene expression data. MOUSE. Data were analyzed using GeneSpring GX version 11 software (Agilent). A stringent FDR with a cutoff of 0.01, and Bonferroni correction for multiple comparisons was used, and genes with a fold change two or greater were identified as differentially expressed. Data reported in this paper are in the Gene Expression Omnibus database (www.ncbi. nlm.nih.gov/geo; accession no. GSE41412 [time series expression data]) (17).

HUMAN. We used a previously published dataset describing genome-wide expression using the Affymetrix HG-U133 plus array in lung tissue from BPD (n = 11) or controls (n = 9) (6). Ingenuity pathway analysis (IPA; Ingenuity Systems, CA) identified canonical pathways. Gene set enrichment analysis (GSEA) was performed using robust multiarray average-normalized expression intensities of all probe sets.

Integrating gene expression and DNA methylation. Data obtained from gene expression analysis was compared with

DNA methylation analysis to identify genes that were significantly altered in both DNA methylation and gene expression. Pathway analysis of these genes was performed with IPA.

Results

Mouse Lung

Gene expression analysis reveals 1,040 differentially expressed genes between newborn versus adult mouse lungs. Gene expression profiles were obtained from total RNA isolated from newborn and adult mouse lungs. Of the more than 40,000 genes on the microarray chip, there were 1,040 genes with a *P* value less than 0.01 and fold change of two or greater between newborn and adult mouse lungs. Of these, 424 genes were up-regulated and 616 genes were down-regulated in adult compared with newborn lungs.

Integrating gene expression with DNA methylation analysis demonstrates 209 differentially methylated and expressed genes, with 95 genes having an inverse correlation. Genome-wide methylation profiles were obtained from DNA isolated from newborn and adults lungs. Differentially methylated genes between the two groups (P < 0.05) were identified and combined with data from gene expression profiles. Of the 1,040 genes with differential gene expression between newborn and adult mouse lungs, 209 genes also had differential DNA methylation. Of these, 95 had an inverse relationship between DNA methylation status and gene expression. A total of 53 genes had increased DNA methylation in newborn compared with adult lungs, with corresponding decreased gene expression in newborn lungs, representing genes possibly silenced by DNA methylation in the newborn lung (Table 1; Figure 1). On the other hand, 42 genes had increased DNA methylation with corresponding decreased gene expression in adult compared with newborn lungs, representing genes possibly silenced by DNA methylation in adult lungs (Table 2; Figure 1).

The remaining 114 genes had the same direction of DNA methylation and gene expression. Of these, 83 genes had both increased DNA methylation and increased gene expression in newborn compared with adult lungs (*see* Table E1 in the online supplement), and 31 genes had both

increased DNA methylation and increased gene expression in adult compared with newborn lungs (Table E2).

Validation of gene expression of matrix metallopeptidase (MMP) 3 (increased DNA methylation, decreased mRNA in newborn) and tenascin C (TNC; increased DNA methylation and decreased mRNA expression in adult) confirmed the direction of gene expression seen on microarray (newborn versus adult mRNA/glyceraldehyde 3-phosphate dehydrogenase: MMP3, 0.009 \pm 0.003 versus 1.33 ± 0.19 ; TNC, 35.4 ± 6.6 versus 2.40 \pm 0.5; all, P < 0.05). DNA methylation of MMP3 and TNC was additionally confirmed by bisulfite conversion of newborn and adult mouse lung DNA, followed by PCR and sequencing (see Figure E1 in the online supplement). DNA methylation of transmembrane and coiled-coil domain family 3 and CMP deaminase was confirmed by pyrosequencing (Figure E2).

Pathway analysis. IPA of genes possibly silenced by DNA methylation in newborn mouse lungs revealed six gene networks (Table E3 and Figures E3–E8), whereas IPA of the genes possibly silenced by DNA methylation in adult lungs revealed four gene networks (Table E4 and Figures E9–E12). The top networks were associated with several relevant functional categories, including cellular development, cellular growth and proliferation, cellular assembly and organization, cell-to-cell signaling and interaction, organ morphology, and inflammatory response.

Human Lung

As we used two separate cohorts of infants with BPD (the gene expression dataset from the study of Bhattacharya and colleagues [6], Rochester cohort, and the samples used for DNA methylation analyses from UAB), we first compared gene expression in these two cohorts. Expression of the four genes with the maximum fold change increase in the Rochester cohort was highly increased in the UAB cohort as well (carboxypeptidase A3-Rochester, 7.14-fold increase; UAB, 12.2-fold increase; chemokine [C-C motif] ligand [CCL] 18-Rochester, 6.74-fold increase; UAB, 17.7-fold increase; Ig heavy constant α 1—Rochester, 6.9-fold increase; UAB, 12.2-fold increase; tryptase α/β 1-Rochester, 6.16-fold increase; UAB, 4.5-fold increase).

DNA methylation studies identify 149 genes differentially methylated in BPD. DNA methylation profiles were obtained from total DNA isolated and restored from BPD and control (term and preterm) FFPE lung tissue samples. By comparing β -subset-quantile within array normalization values, 149 genes located in 286 loci were identified to have differential methylation in BPD lungs compared with preterm lungs with FDR of less than 0.05.

Integrating DNA methylation with gene expression data reveals 32 genes differentially methylated and expressed, with 23 genes having an inverse correlation. Gene expression for the 149 identified genes residing within 286 loci of abnormal methylation was assessed using a total of 432 probe sets; 32 of 149 differentially methylated genes (22%) were also significantly dysregulated by gene expression in BPD lung tissue, representing a significant fourfold enrichment (Fisher exact P < 0.001; Table 3; Figure 1). The magnitude of expression changes for these genes was modest (≤ 2 -fold). Three genes were independently identified as differentially expressed by multiple probe sets: KIAA1217 (×3), EH-domain containing 4 (×2), and BAI1-associated protein 2 (\times 2).

Of the 32 genes identified, 23 genes had opposite directions of methylation and expression changes. One gene, zinc finger protein 438 (ZNF438), had decreased methylation associated with increased expression in BPD (Table 4; Figure 1), and 22 genes had increased methylation corresponding with decreased expression in BPD (Table 5; Figure 1).

The remaining nine genes had the same direction of methylation and expression. One gene, BAI1-associated protein 2, had decreased methylation associated with decreased expression in BPD (Table E5), and eight genes had increased methylation and increased expression in BPD (Table E6). The location of methylated CpG sites in relation to the gene was summarized and showed that, in general, methylation of CpG sites located in enhancers and north shores tend to have an opposite direction of gene expression (Table E7).

Validation of gene expression of KIAA1217 and ZNF438 by real-time RT-PCR confirmed the direction of gene expression seen on microarray (preterm versus BPD messenger RNA/glyceraldehyde 3-phosphate dehydrogenase—KIAA1217: 3.00 ± 1.16 versus 0.67 ± 0.33 [4-fold decrease in BPD]; ZNF438: 0.00056 + 0.0003

Table 1. Genes with Increased DNA Methylation and Decreased Messenger RNA Expression in Newborn Mouse Lung Compared with Adult Mouse Lung, Arranged in Order of Increasing *P* Value

Gene				Adjusted	Fold Change in Gene	Fold Enrichment
Symbol	Probe Name	Gene Title	Entrez Gene	P Value	Expression	in Methylation
Chi3l3	A_51_P167292	Chitinase 3-like 3	12655	7.4E-08	-58.9	19.3
Nrn1	A_51_P308844	Neuritin 1	68404	1.7E-07	-11.4	22.6
Lrp2	A_52_P285470	Low-density lipoprotein receptor-related protein 2	14725	2.4E-07	-5.1	20.7
Inmt	A 51 P162162	Indolethylamine N-methyltransferase	21743	4.7E-07	-176.5	41.4
Scube2	A_55_P2232988	Signal peptide, CUB domain, EGF-like 2	56788	5.5E-07	-3.3	41.4
Mmp3	A_51_P255699	Matrix metallopeptidase 3	17392	7.2E-07	-144.4	11.09
Ggct	A_52_P641758	γ-Glutamylcyclotransferase	110175	1.2E-06	-2.2	8.28
Cd209a*	A_55_P2018061	CD209a antigen	170786	1.8E-06	-19.7	8.775
Aox3	A_52_P16752	Aldehyde oxidase 3	71724	2.8E-06	-8.3	33.11
Sod3	A_55_P2077558	Superoxide dismutase 3, extracellular	20657	2.9E-06	-11.3	37.94
Bcl6	A_52_P161495	B-cell leukemia/lymphoma 6	12053	4.3E-06	-4.2	45.07
Crebl2	A_52_P541270	cAMP responsive element binding protein–like 2	232430	4.8E-06	-4.2	45.07
Zbtb4	A_55_P2165655	Zinc finger and BTB domain containing 4	75580	1.2E-05	-2.2	45.07
Ccr6	A_55_P2108943	Chemokine (C-C motif) receptor 6	12458	2.2E-05	-9.2	6.34
H2-Ob*	A_55_P2082929	Histocompatibility 2, O region β locus	15002	2.2E-05	-14.4	11.04
Sp110	A_55_P2152566	Sp110 nuclear body protein	109032	2.8E-05	-3.2	45.07
Lilrb3	A_55_P2097279	Leukocyte Ig–like receptor, subfamily B (with TM and ITIM domains),	18733	1.1E-04	-2.5	14.28
St3gal1	A_65_P03728	member 3 ST3 β-galactoside α-2,3- sialyltransferase 1	20442	1.2E-04	-2.1	15.57
Efemp1	A_55_P2048767	Epidermal growth factor-containing fibulin-like extracellular matrix protein 1	216616	1.3E-04	-4.9	9.03
Adra1a	A 52 P424778	Adrenergic receptor, α 1a	11549	1.6E-04	-20.5	7.95
B2 m	A_51_P129012	β -2 microglobulin	12010	1.7E-04	-4.2	19.66
BC006779	A_55_P1959953	cDNA sequence BC006779	229003	2.1E-04	-2.3	12.17
Prdx6	A_55_P2103561	Peroxiredoxin 6	11758	2.1E-04	-2.8	41.38
Angpt2	A_51_P201982	Angiopoietin 2	11601	2.2E-04	-2.6	9.44
Lims2	A_55_P2174203	LIM and senescent cell antigen-like domains 2	225341	2.6E-04	-3.5	41.38
Prkca	A_52_P72587	Protein kinase C, θ	18761	2.6E-04	-3.0	9.36
Scml4	A_55_P2020338	Sex comb on midleg–like 4 (Drosophila)	268297	3.3E-04	-4.3	41.38
Aldh1a1	A_51_P334942	Aldehyde dehydrogenase family 1, subfamily A1	11668	3.6E-04	-4.9	9.22
Gbp5	A 52 P327664	Guanylate binding protein 5	229898	3.9E-04	-4.0	54.09
Slc9a4	A_55_P1973588	Solute carrier family 9 (sodium/	110895	4.0E-04	-15.5	33.11
Sh3bp5	A_55_P2049479	hydrogen exchanger), member 4 SH3-domain binding protein 5	24056	4.0E-04	-2.4	54.09
Tmcc3*	A_52_P16877	(BTK-associated) Transmembrane and coiled coil	319880	4.8E-04	-2.8	9.7
Cd209a*	A_51_P133884	domains 3 CD209a antigen	170786	5.7E-04	-17.9	8.76
Gria1	A_51_P133664 A_55_P2113758	Glutamate receptor, ionotropic,	14799	5.7E-04 7.8E-04	-7.8	33.84
Rasgrp1	A_55_P1969650	AMPA1 (α 1) RAS guanyl releasing protein 1	19419	8.4E-04	-5.2	22.15
Kcnj15	A_55_P1969650 A_55_P2164090	Potassium inwardly rectifying	16516	8.4E-04 8.4E-04	-5.2 -2.3	45.07
Cabl		channel, subfamily J, member 15	10000	1 05 00	0.4	11 00005
Cobl	A_55_P1995243	Cordon-bleu	12808	1.0E-03	-2.4	11.38625
Heatr1 Blnk	A_66_P108019	HEAT repeat containing 1 B cell linker	217995 17060	1.1E-03	-2.0 -5.4	7.57
Igfbp3	A_55_P2002757 A_52_P253179	B cell linker Insulin-like growth factor binding	16009	1.1E-03 1.3E-03	-5.4 -6.1	16.63 12.41
iginha	A_JZ_FZJJ119	protein 3	10009	1.50-05	0.1	12.41
		•				(2

(Continued)

Table 1. (Continued)


Gene Symbol	Probe Name	Gene Title	Entrez Gene	Adjusted <i>P</i> Value	Fold Change in Gene Expression	Fold Enrichment in Methylation
Adam3	A_55_P2025721	A disintegrin and metallopeptidase domain 3 (cyritestin)	11497	2.1E-03	-14.4	45.07
Gm281	A_55_P1970110	Predicted gene 281	238939	2.3E-03	-11.1	6.03
Klrb1b	A_55_P2106681	Killer cell lectin-like receptor subfamily B member 1B	80782	2.5E-03	-5.1	24.83
Spnb5	A_55_P1994504	Spectrin β 5	640524	3.7E-03	-4.0	13.79
Sh2d1a	A_55_P1958146	SH2 domain protein 1A	20400	4.2E-03	-6.5	15.76
Wisp2	A_51_P390804	WNT1 inducible signaling pathway protein 2	22403	4.4E-03	-15.0	14.77
Tmcc3*	A_51_P189272	Transmembrane and coiled coil domains 3	319880	4.8E-03	-3.7	9.7
Phf15	A 55 P2139753	PHD finger protein 15	76901	4.9E-03	-3.3	20.69
Cdhr3	A_66_P122115	Cadherin-related family member 3	68764	6.1E-03	-4.1	49.58
Stat4	A_51_P177092	Signal transducer and activator of transcription 4	20849	6.2E-03	-5.7	8.28
Cd19	A_55_P2079079	CD19 antigen	12478	7.1E-03	-5.2	33.11
H2-Ob*	A_66_P130916	Histocompatibility 2, O region β locus	15002	7.6E-03	-8.7	11.04
Mtmr7	A_66_P117578	Myotubularin-related protein 7	54384	7.8E-03	-2.6	18.02
Ccl5	A 52 P638459	Chemokine (C-C motif) ligand 5	20304	9.1E-03	-11.2	33.86
Ampd3	A_52_P502754	Adenosine monophosphate deaminase 3	11717	9.5E-03	-2.7	82.76

Definition of abbreviations: AMPA1, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor; BTB, BR-C, ttk, and bab domain; BTK, Bruton's tyrosine kinase; CUB, complement C1r/C1s, Uegf, Bmp1 domain; EGF, epidermal growth factor; HEAT, Huntingtin, elongation factor 3, the PR65/A subunit of protein phosphatase 2A, and the lipid kinase Tor; ITIM, immunoreceptor tyrosine-based inhibition motif; LIM, Lin11, Isl-1, and Mec-3 proteins; PHD, plant homeodomain protein; TM, transmembrane; RAS, rat sarcoma; SH, Src Homology 2; ST3, sialyltransferase 3; WNT, wingless-type MMTV integration site family. *Genes with methylation in more than one locus.

versus 0.0058 + 0.007 [10-fold increase in BPD]; all *P* < 0.05).

Pathway analysis. Pathway analysis of gene expression of all 149 genes (represented by 432 probe sets) affected by methylation identified nine canonical pathways (Table E8). These pathways, some

of which deal with progenitor cell differentiation, were not previously understood to be important in lung development and/or BPD. One pathway of potential significant interest was Wnt/ β -catenin signaling. When the list was limited to the 32 significantly dysregulated



genes (represented by 36 probe sets), seven pathways were identified (Table 6; Figure 1). A single pathway (cardiomyocyte differentiation) was common to both analyses. The remaining six pathways included ErbB receptor tyrosine kinase/ neuregulin signaling (18), as well as a nitric oxide-related pathway, both of which have been previously implicated in lung development and BPD pathogenesis.

GSEA. GSEA comparing gene expression of the 149 genes with altered methylation status from lung tissues from BPD (n = 11) to controls (n = 9) identified 74 gene sets as up-regulated in BPD out of 190 gene sets that passed the size threshold (minimum = 5; maximum = 500), five of which were significant (P < 0.05; Table E9). GSEA also identified 116 gene sets as upregulated in controls compared with BPD out of 190 gene sets that passed the size threshold (minimum = 5; maximum = 500), seven of which were significant (P < 0.05; Table E10).

Comparing DNA methylation levels between preterm and term lung identified 437 genes with differential methylation potentially involved in normal alveolar septation. DNA methylation data obtained from preterm lung were compared with

Figure 1. Overall approach in this project with summary and location of results. BPD, bronchopulmonary dysplasia.

4C/FPO

 Table 2. Genes with Increased DNA Methylation and Decreased Messenger RNA Expression in Adult Mouse Lung Compared with

 Newborn Mouse Lung, Arranged in Order of Increasing P Value

Gene Symbol Probe Name Gene Title Entrez Gene Aguetad P Value Fold Environment P Value Fold Environment P Value Col/2761 A.52, P490088 Collagen, type XXVII, n 1 373864 4.5E-09 -18.4 26.39 Skp2 A.66, P134481 S-phase kinase-associated protein 2 (p45) 225579 1.3E-06 -4.0 43.98 Camk1 g A.55, P2020337 Calleur/calmodilin-dependent protein 2 (p45) 215303 8.7E-06 -4.0 43.98 Camk1 g A.55, P202088 Calmocionide reduct ase M1 20133 1.0E-06 -3.9 20.16 Collads A.55 P200288 Detruncionide reduct ase M1 20133 1.0E-05 -5.1 35.19 Shiaa2 A.55 P2002898 Detruncionida reduct ase M1 20133 2.0E-05 -5.1 35.19 Shiaa2 A.55 P2002898 E2F transcription factor 7 52679 3.2E-05 -10.3 52.78 Wift A.51 P404626 Writ inhibitory factor 1 24117 3.9E-05 -2.8 52.23 Cahn1 A.55 P20498972							
Slc27a6 A_55_P2039379 Soluté carrier family 27 (datty acid 22579 1.3E-06 -18.4 26.39 Skp2 A_66_P134481 S-phase kinase-associated 27401 5.6E-06 -4.0 43.98 Camk1 g A_55_P2020331 Calcium/calmodulin-dependent 215303 8.7E-06 -4.2.8 43.98 Camk1 g A_55_P202023 Ribonucleotide reductase M1 20133 1.0E-05 -3.9 20.16 Collead A_55_P202023 Retinoic acid early transcript 1E 379043 1.4E-05 -2.4 43.39 Sheaz A_55_P2062536 Fit mascription factor 7 5.2679 3.2E-05 -10.3 32.258 Sheaz A_55_P2062538 EF transcription factor 7 5.2679 3.2E-05 -3.0 43.98 Calcium A A_55_P2062538 Ribonucleotide reductase M2 20135 7.3E-05 -9.2 9.87 Auts2 A_51_P204972 Batarin 13171 8.2E-05 -3.8 52.78 Polima3 A_52_P2069724 Retain 13311 8.3E-05		Probe Name	Gene Title			in Gene	Enrichment In
Slc27a6 A_55_P2033379 Soluté carrier taminy 27 (datty acid 22579 1.3E-06 -18.4 26.39 Skp2 A_66_P134481 S-phase kinase-associated 27401 5.6E-06 -4.0 43.98 Camk1 g A_55_P2020331 Calcium/calmodulin-dependent 215303 8.7E-06 -4.2.8 43.98 Camk1 g A_55_P202082 Ribonucleotide reductase M1 20133 1.0E-05 -3.9 20.16 Colead A_55_P202082 Reinoic acid early transcript 1E 379043 1.4E-05 -2.4 43.39 Shiaaz A_55_P2002598 E2F transcription factor 7 5.2679 3.2E-05 -10.3 32.258 Shiaaz A_55_P2002598 E2F transcription factor 8 109974 5.7E-05 -2.6 40.32 Cult A_55_P206972 Ribonucleotide reductase M2 20135 7.3E-05 -3.8 52.78 Polim3 A_52_P509531 PD2 and LIM domain 3 53318 8.3E-05 -6.8 43.98 Ptim3 A_51_P206972 Eastin 1.377 -6.4 <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>							
Stp2 A 66_P134481 S-phask kinase-associated protein 2 (p45) 2701 5.6E-06 -4.0 43.98 Camk1 g A.55_P202033 Calcium/calmodulin-dependent protein kinase I y 215303 8.7E-06 -42.8 43.98 Rm1 A.51_P50208 Ribroucleotide reductase M1 20133 1.0E-05 -3.9 20.16 Col6a3 A.52_P479262 Collagen, type VI, a 3 12835 1.3E-05 -2.4 48.39 Reat1e A.55_P2020383 E2F transcription factor 7 5.0679 3.2E-05 -10.3 52.278 Wit1 A.51_P2008383 E2F transcription factor 7 1.08961 3.3E-05 -10.3 52.78 Auts2 A.51_P200833 E2F transcription factor 7 1.08961 3.3E-05 -2.8 52.23 Cdn11 A.55_P2173982 Riborulcotide reductase M2 20135 7.3E-06 -2.8 9.87 Find A.51_P398191 Auts2 A51_P398191 Partrain-related gene 19281 1.2E-04 -1.1 1.651 4.65 9.87 Find	Col27a1	A_52_P480088	Collagen, type XXVII, α 1		4.5E-09	-4.0	26.39
Skp2 A.66_P134481 S-phase kinase-associated protein 2 (P45) 27401 5.8E-06 -4.0 43.98 Camk1 g A.55_P2020331 Calcium/calmodulin-dependent protein kinase 1 v 215303 8.7E-06 -42.8 43.98 Rm1 A.51_P502082 Ribonucleotide reductase M1 20133 1.0E-05 -2.4 48.39 Raet1e A.55_P2020835 Retinoic acid early transcript 1E 379043 1.4E-05 -2.6 10.16 Shisa2 A.55_P2006298 E2F transcription factor 7 52679 3.2E-05 -10.8 3.22.6 E276 A.55_P2062998 E2F transcription factor 7 52679 3.2E-05 -10.8 3.22.6 Cdn11 A.55_P2181366 Cadhern 11 12552 6.0E-05 -3.0 43.98 Fmr2 A.55,P2181356 Cadhern 11 13117 8.3E-05 -6.8 52.73 Palim3 A.52 P609972 Elastin 13117 8.3E-05 -6.8 52.76 Palim3 A.51 P313403 Sperm-associated antigen 5 54141 1.0E-04	Slc27a6	A_55_P2039379		225579	1.3E-06	-18.4	26.39
Camk1 g A, 55, P220333 Calcium/calmodulin-dependent 215333 8.7E-06 -42.8 43.98 Rm1 A, 51, P502082 Ribonucleotide reductase M1 20133 1.3E-05 -3.9 20.16 Collaga, type VI, α 3 1235 1.3E-05 -2.4 48.39 Raet1e A, 55, P2115955 Retinoic acid early transcript 1E 379043 1.4E-05 -2.6 10.16 Shisa2 A, 55, P2062598 E2F transcription factor 7 52679 3.2E-05 -10.8 32.26 Wift A, 51, P484526 Writ inhibitory factor 1 24117 3.9E-05 -7.6 40.32 Cahl 11 A, 55, P2173982 E1 transcription factor 8 108374 5.7E-05 -9.2 9.87 Firm2 A, 55, P2173982 E1 transcription factor 1 12522 6.0E-05 -3.0 43.88 Spag5 A, 51, P51353 D22 and LIM domain 3 53318 8.38=-05 -8.9 9.837 Ptidim A, 56, P133404 RicEN cDNA 2810417H13 gene 52614141 10E-04 -11.1	Skp2	A_66_P134481		27401	5.6E-06	-4.0	43.98
	Camk1 g	A_55_P2020331	Calcium/calmodulin-dependent	215303	8.7E-06	-42.8	43.98
Reat Ite A 55 P2115955 Retinoic acid early transcript 1E 379043 1.4E=05 -2.6 10.16 Shisa 2 A 55 P2062598 E2F transcription factor 7 52679 3.2E=05 -10.3 52.78 Wift A 55 P2062598 E2F transcription factor 7 52679 3.2E=05 -10.3 52.78 Wift A 51 P484526 Wht inhibitory factor 1 24117 39E=05 -7.6 40.32 Cdh11 A 55 P2173926 Cadherin 11 12552 6.0E=05 -3.0 43.98 Phm2 A 55 P2173926 PD2 and LIM domain 3 53318 8.3E=05 -6.9 48.39 Spag5 A 51 P513503 Sperm-associated antigen 5 54141 1.0E=04 -11.1 16.13 Pb3 A 51 P513503 Sperm-associated antigen 5 54141 1.0E=04 -5.1 43.98 2810417H13Rik A 66 P13404 RIKEN cDNA 281047H17H3 gene 680026 1.3E=04 -13.6 9.6 Dtd* A 51 P2421597 DacM/P dearninase 320127 2.3E=04 -6.2<							
Shisa2 A_51_P406649 Shisa homolog 2 (Xenopus laevis) 219134 20E-05 -5.1 35.19 E27 A_55_P2005398 E2F transcription factor 7 52679 3.2E-05 -10.8 32.26 E28 A_55_P200533 E2F transcription factor 8 109961 3.2E-05 -10.8 52.78 Auts2 A_51_P398191 Autism susceptibility candidate 2 319974 5.7E-05 -2.8 52.23 Cdh11 A_55_P2173982 Ribonucleotide reductase M2 20135 7.3E-05 -9.2 9.37 Flm2 A_52_P609972 Elastin 13717 8.3E-05 -6.9 48.39 Spag5 A_51_P513303 Sperm-associated antigen 5 54141 10E-04 -1.1.1 16.13 2810417H138ik A_66_P133404 RIKEN CDNA 2810417H1743 gene 68026 1.3E-04 -7.6 61.57 Dgki A_51_P36411 Diaxlyllycerol kinase, iota 320127 2.3E-04 -5.5 61.57 Dgki A_51_P247809 Potassium large conductance 16531 3.7E-04							
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$							
E28 A_55_P2000833 E2F transcription factor 8 108861 3.3E-05 -10.3 52.78 Auts2 A,51_P308191 Autism susceptibility candidate 2 319974 5.7E-05 -7.6 40.32 Cdn11 A,55_P2173982 Cadherin 11 12552 6.0E-05 -3.0 43.98 Rinn A,55_P2173982 Ribonucleotide reductase M2 20135 7.3E-05 -9.2 9.87 Eln A,55_P2679531 PDZ and LIM domain 3 53318 8.3E-05 -6.9 48.39 Spag5 A,51_P51350 Sperm-associated antigen 5 54141 1.0E-04 -11.1 16.13 PtX3 A,51_P136411 ONC-5 Pentraxin-related gene 68026 1.3E-04 -5.5 61.57 Dgki A,51_P136411 Diacylg/ycerol kinase, iota 320127 2.3E-04 -6.5 61.57 Dgki A,51_P136411 Diacylg/ycerol kinase, iota 320127 2.3E-04 -2.7 48.38 CdCM* A,55_P2057142 Predicted gene 6531 624855 5.2E-04							
Wiff A_51_P44526 Wrt inhibitory factor 1 24117 3.9E-05 -7.6 40.32 Cdh11 A,55_P2181366 Cadherin 11 1252 6.0E-05 -3.0 43.88 Prm2 A,55_P2173982 Ribonucleotide reductase M2 20135 7.3E-05 -9.2 9.87 Pdim3 A,52_P579531 PDZ and LIM domain 3 53318 8.3E-05 -6.9 48.39 Spag5 A,51_P513530 Sperm-associated antigen 5 54141 1.0E-04 -11.1 16.13 PtX3 A,51_P374726 Pentraxin-related gene 19284 1.2E-04 -5.5 61.57 Qs10417H138Ik A,66_P129566 UNC5 homolog C (Caenorhabditis 22253 1.6E-04 -7.1 61.57 Dctd' A,55_P237846 OKMP deaminase 3201685 2.7E-04 -6.2 32.26 Kcnma1 A_55_P2421597 Tenasofi C 21923 3.9E-04 -2.6 7.52.78 Dctd' A,55_P2421597 Tenasofi C 21923 3.9E-04 -2.6 3.2.26				52679	3.2E-05	-10.8	
Auts2 A.55_P28181961 Autism susceptibility candidate 2 319974 5.7E-05 -2.8 52.23 Rmm2 A.55_P2161366 Cadherin 11 12552 6.0E-05 -3.0 43.88 Rmm2 A.55_P2173982 Ribonucleotide reductase M2 20135 7.3E-05 -9.2 9.87 Ein A.52_P579531 PDZ and LIM domain 3 53318 8.3E-05 -6.9 44.39 Spag5 A.51_P513530 Sperm-associated antigen 5 54141 1.0E-04 -11.1 16.13 2810417H138ik A.66_P129566 Pentrxain-related gene 19288 1.2E-04 -5.5 61.57 Dgki A.51_P136411 Diacy(glycerol kinase, iota 320127 2.3E-04 -6.2 32.26 Kcnma1 A.55_P237846 dCMP deaminase 320685 2.7E-04 -6.2 32.26 Kcnma1 A.55_P2421597 Tenascin C 21923 3.9E-04 -6.3 43.39 Tnc* A.55_P2421597 Tenascin C 21923 3.9E-04 -6.3 43.39	E2f8	A_55_P2000833	E2F transcription factor 8	108961		-10.3	
	Wif1	A_51_P484526	Wnt inhibitory factor 1		3.9E-05		
Rmm2 A_55_P2173982 Ribonucleotide reductase M2 2013 7.3E-05 -9.2 9.87 Pdim3 A_52_P609972 Elastin 13717 8.3E-05 -6.9 48.39 Spag6 A_51_P374726 Pentraxin-related gene 19288 1.2E-04 -11.1 16.13 PbX3 A_51_P374726 Pentraxin-related gene 19288 1.2E-04 -13.6 9.6 2810417H138ik A_66_P129566 UNC-5 homolog C (Caenorhabditis 22253 1.6E-04 -7.1 61.57 Dgki A_51_P136411 Diacylglycorol kinase, iota 320127 2.3E-04 -5.5 61.57 Dctd* A_55_P2378486 Potassium large conductance 16531 3.7E-04 -6.2 32.26 Konma1 A_55_P2421597 Tenascin C 21923 3.9E-04 -6.7 52.78 Dctd* A_55_P2421597 Tenascin C 21923 3.9E-04 -2.3 32.26 Gm6531 A_55_P245142 Predicted gene 6531 624855 5.2E-04 -13.0 32.26		A_51_P398191	Autism susceptibility candidate 2	319974			
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	Cdh11	A_55_P2181356	Cadherin 11			-3.0	
PdIm3A 5252 52PDZ and LIM domain 35318 53188.3E 65-6.948.39Spag5A 51P31426Sperm-associated antigen 5541411.0E 64-11.116.13Ptv3A 51P317476Pentraxin-related gene192881.2E 64-5.143.982810417H13RikA 66P133404RIKEN cDNA 2810417H13 gene680261.3E 646-7.161.57DgkiA 51P136411Diacytglycerol kinase, iota3201272.3E 2.3E-6.561.57DgkiA 52P13826Diacytglycerol kinase, iota3201272.3E 2.3E-6.232.26Kcnma1A 55P2421597Tenascin C219233.9E 2.2E-6.232.26Chd*A 52P2421597Tenascin C219233.9E 2.2E-6.348.39Dctd*A 55P205142Predicted gene 65316248555.2E 2.2E-6.348.39Ext1A 51P41689Exostoses (multiple) 1140425.8E 2.8E-0.4-2.332.26Gm6531A 55P2024259Pacental specific protein 16.6963.3E 2.2E-0.4-3.843.98Tt2A 55P2024528Transcription termination factor, RNA740441.1E 2.2E-0.4-3.843.98Prdm8A 55P2024529P1204039Replication factor C (activator 1) 576.66-0.4-3.843.98	Rrm2		Ribonucleotide reductase M2	20135	7.3E-05	-9.2	
Spag5 A_51_P513530 Sperm-associated antigen 5 54141 1.0E-04 -11.1 16.13 Ptx3 A_51_P374726 Pentraxin-related gene 19288 1.2E-04 -5.1 43.98 2810417H13Rik A_66_P133404 RIKEN cDNA 2810417H13 gene 68026 1.3E-04 -13.6 9.6 Unc5c A_66_P133404 RIKEN cDNA 2810417H13 gene 68026 1.3E-04 -7.1 61.57 Dgki A_51_P136411 Diacylglycerol kinase, iota 320127 2.3E-04 -6.2 32.26 Kcnma1 A_55_P2378466 Potassium large conductance 16531 3.7E-04 -2.7 48.38 Calcium-activated channel, subfamily M, \alpha member 1 - -13.0 32.26 Dctd* A_55_P207142 Predicted gene 6531 624855 5.2E-04 -6.3 48.39 Exot 5 A_51_P24639 Replication factor (activator 1) 5 72151 6.6E-04 -3.8 43.98 Tra A_55_P2062836 Replication factor (activator 1) 5 72151 6.6E-04 -2.8 43.98							52.78
Pix3A_51P374726Pintraxin-related gene192881.2E-04-5.143.982810417H13RikA_66P133404RIKEN cDNA 2810417H13 gen680261.3E-04-7.161.5700000000000000000000000000000000000	Pdlim3					-6.9	
2810417H13Rik A_66_P133404 RIKEN cDNA 2810417H13 gene 68026 1.3E-04 -13.6 9.6 Unc5c A_66_P129566 UNC-5 homolog C (Caenorhabditis 22253 1.6E-04 -7.1 61.57 Dgki A_51_P136411 Diacy[glycerol kinase, iota 320127 2.3E-04 -5.5 61.57 Dctd* A_55_P2378486 CMP deaminase 32065 2.7E-04 -6.2 32.26 Kcnma1 A_55_P2378486 Potassium large conductance 16531 3.7E-04 -2.7 48.38 Calcium-activated channel, subfamily M, α member 1 Tenascin C 21923 3.9E-04 -26.7 52.78 Dctd* A_55_P2057142 Predicted gene 6531 624855 5.2E-04 -6.3 48.39 Ext1 A_51_P44639 Replication factor C (activator 1) 5 72151 6.6E-04 -3.8 43.98 Tft2 A_55_P2024525 PR domain-containing 8 77630 1.2E-03 -2.4 61.57 Placental specific protein 1 56096 1.3E-03 -5.5 56.45							
Unc5c A_66_P129566 UNC-5 homolog C (<i>Caenorhabditis</i> 22253 1.6E-04 -7.1 61.57 Dgki A_51_P136411 Diacylglycerol kinase, iota 320127 2.3E-04 -6.2 32.26 Dctd* A_55_P2378486 Potassium large conductance 16531 3.7E-04 -2.7 48.38 calcium-activated channel, subfamily M, α member 1 Tenascin C 21923 3.9E-04 -26.7 52.78 Dctd* A_55_P2421597 Tenascin C 21923 3.9E-04 -26.7 52.78 Dctd* A_55_P2057142 Predicted gene 6531 624855 5.2E-04 -6.3 48.39 Ext1 A_51_P24639 Replication factor C (activator 1) 5 72151 6.6E-04 -3.8 43.98 Tft2 A_55_P2024825 Pracental specific protein 1 56096 1.3E-03 -22.4 61.57 Plact A_55_P204505 Placental specific protein 1 56096 1.3E-03 -27.3 32.26 Shisa3 A_55_P218104 Shisa homolog 3 (Xenopus laevis) 330096 1.4E-03<					1.2E-04	-5.1	
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	2810417H13Rik		RIKEN cDNA 2810417H13 gene			-13.6	9.6
Dctd* A. 55_P183826 dCMP deaminase 320685 2.7E=04 -6.2 32.26 Kcnma1 A.55_P2378486 Potassium large conductance calcium-activated channel, subfamily M, α member 1 16531 3.7E=04 -2.7 48.38 Tnc* A.55_P2421597 Tenascin C 21923 3.9E=04 -13.0 32.26 Gm6531 A.55_P2057142 Predicted gene 6531 624855 5.2E=04 -6.3 48.39 Ext1 A.51_P416689 Exostoses (multiple) 1 14042 5.8E=04 -2.3 32.26 Rfc5 A_51_P246339 Replication factor C (activator 1) 5 72151 6.6E=04 -3.8 43.98 Tf12 A_55_P2062836 Transcription termination factor, RNA 74044 1.1E=03 -2.1 52.78 Pidma8 A_55_P1962279 Pla cental specific protein 1 56096 1.3E=03 -2.4 61.57 Plac1 A_55_P195303 Leucine rich repeat containing 4B 272381 1.5E=03 -5.5 56.45 Lrrc4b* A_55_P2154749 Shisa homolog 6 (Xenopus laevis)	Unc5c	A_66_P129566	elegans)	22253			
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	Dgki		Diacylglycerol kinase, iota			-5.5	
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	Dctd*						32.26
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	Kcnma1	A_55_P2378486	calcium-activated channel,	16531	3.7E-04	-2.7	48.38
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	Tnc*	A_55_P2421597	Tenascin C	21923		-26.7	52.78
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	Dctd*	A_52_P301085	dCMP deaminase	320685		-13.0	32.26
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	Gm6531	A_55_P2057142	Predicted gene 6531	624855	5.2E-04	-6.3	48.39
Ttf2A_55_P2062836Transcription termination factor, RNA polymerase II740441.1E-03-2.152.78Prdm8A_55_P2024525PR domain-containing 8776301.2E-03-2.461.57Plac1A_55_P1962279Placental specific protein 1560961.3E-03-27.332.26Shisa3A_55_P2181104Shisa homolog 3 (Xenopus laevis)3300961.4E-03-14.840.32Lrrc4b*A_55_P2195303Leucine rich repeat containing 4B2723811.5E-03-5.556.45Lrrc4b*A_55_P21016079Predicted gene 70926327782.0E-03-2.143.98Shisa6A_55_P2016079Predicted gene 70926327782.0E-03-5.248.38Ctnna2*A_55_P2075726Catenin (cadherin-associated123862.6E-03-5.248.38Ctnna2*A_51_P401263Essential meiotic endonuclease 1 protein), α 22684652.6E-03-7.624.19ErmapA_51_P391716Erythroblast membrane-associated270282.7E-03-7.740.32Sox9A_52_P185070Roundabout homolog 1 (Drosophila)198763.5E-03-3.024.19Sox9A_52_P214630SRY-box containing gene 9206824.4E-03-6.861.57Dido1A_52_P355169Tenascin C219234.6E-03-54.352.78		A_51_P416689	Exostoses (multiple) 1				
$\begin{array}{c c c c c c c c c c c c c c c c c c c $			Replication factor C (activator 1) 5				
Plac1 $A_55^-P1962279$ Placental specific protein 1 56096 $1.3E-03$ -27.3 32.26 Shisa3 $A_55^-P2181104$ Shisa homolog 3 (Xenopus laevis) 330096 $1.4E-03$ -14.8 40.32 Lrrc4b* $A_55^-P218503$ Leucine rich repeat containing 4B 272381 $1.5E-03$ -5.5 56.45 Lrrc4b* $A_55^-P2125982$ Leucine rich repeat containing 4B 272381 $1.7E-03$ -5.5 56.45 Gm7092 $A_55^-P2016079$ Predicted gene 7092 632778 $2.0E-03$ -2.1 43.98 Shisa6 $A_55^-P2154749$ Shisa homolog 6 (Xenopus laevis) 380702 $2.2E-03$ -5.2 48.38 Ctnna2* $A_55^-P2075726$ Catenin (cadherin-associated 12386 $2.6E-03$ -7.6 24.19 homolog 1 (Schizosaccharomyces protein), α 2 $a_55^-P214630$ Essential meiotic endonuclease 1 protein), α 2 2.68465 $2.6E-03$ -7.7 40.32 Ermap $A_51_P391716$ Erythroblast membrane-associated 27028 $2.7E-03$ -7.7 40.32 Robo1 $A_55_P1985070$ Roundabout homolog 1 (Drosophila) 19876 $3.5E-03$ -3.0 24.19 Sox9 $A_52_P214630$ SRY-box containing gene 9 20682 $4.4E-03$ -6.8 61.57 Tnc* $A_55_P2430472$ Death inducer-obliterator 1 23856 $4.6E-03$ -3.4 40.32			polymerase II	74044			
Shisa3 $A_{-55}^{-}P2181104$ Shisa homolog 3 (Xenopus laevis) 330096 $1.4E-03$ -14.8 40.32 Lrrc4b* $A_{-55}^{-}P1953503$ Leucine rich repeat containing 4B 272381 $1.5E-03$ -5.5 56.45 Lrrc4b* $A_{-55}^{-}P2125982$ Leucine rich repeat containing 4B 272381 $1.7E-03$ -5.5 56.45 Gm7092 $A_{-55}^{-}P216079$ Predicted gene 7092 632778 $2.0E-03$ -2.1 43.98 Shisa6 $A_{-55}^{-}P2154749$ Shisa homolog 6 (Xenopus laevis) 380702 $2.2E-03$ -5.2 48.38 Ctnna2* $A_{-55}^{-}P2075726$ Catenin (cadherin-associated 12386 $2.6E-03$ -7.6 24.19 Eme1 $A_{-51}^{-}P401263$ Essential meiotic endonuclease 1 protein), $\alpha 2$ 268465 $2.6E-03$ -7.6 24.19 Ermap $A_{-51}^{-}P391716$ Erythroblast membrane-associated protein 27028 $2.7E-03$ -7.7 40.32 Robo1 $A_{-52}^{-}P1985070$ Roundabout homolog 1 (Drosophila) 19876 $3.5E-03$ -3.0 24.19 Sox9 $A_{-52}^{-}P214630$ SRY-box containing gene 9 20682 $4.4E-03$ -6.8 61.57 Tnc* $A_{-52}^{-}P2430472$ Death inducer-obliterator 1 23856 $4.6E-03$ -3.4 40.32	Prdm8						
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	Plac1						
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$							
Gm7092A_55_P2016079Predicted gene 7092 632778 $2.0E-03$ -2.1 43.98 Shisa6A_55_P2154749Shisa homolog 6 (Xenopus laevis) 380702 $2.2E-03$ -5.2 48.38 Ctnna2*A_55_P2075726Catenin (cadherin-associated protein), α 2 12386 $2.6E-03$ -3.6 52.78 Eme1A_51_P401263Essential meiotic endonuclease 1 homolog 1 (Schizosaccharomyces pombe) 268465 $2.6E-03$ -7.6 24.19 ErmapA_51_P391716Erythroblast membrane-associated protein 27028 $2.7E-03$ -7.7 40.32 Robo1A_55_P1985070 Sox9Roundabout homolog 1 (Drosophila) Sox919876 $3.5E-03$ -3.0 24.19 Sox9A_52_P214630 SRY-box containing gene 9 20682 $4.4E-03$ -6.8 61.57 Tnc*A_55_P2430472Death inducer-obliterator 1 23856 $4.6E-03$ -3.4 40.32							
Shisa6 $A_{55}^{-}P2154749$ Shisa homolog 6 (Xenopus laevis) 380702 $2.2E-03$ -5.2 48.38 Ctnna2* $A_{55}^{-}P2075726$ Catenin (cadherin-associated 12386 $2.6E-03$ -3.6 52.78 Eme1 $A_{51}^{-}P401263$ Essential meiotic endonuclease 1 homolog 1 (Schizosaccharomyces pombe) 268465 $2.6E-03$ -7.6 24.19 Ermap $A_{51}^{-}P391716$ Erythroblast membrane-associated protein 27028 $2.7E-03$ -7.7 40.32 Robo1 $A_{55}^{-}P1985070$ Roundabout homolog 1 (<i>Drosophila</i>) 19876 $3.5E-03$ -3.0 24.19 Sox9 $A_{52}^{-}P214630$ SRY-box containing gene 9 20682 $4.4E-03$ -6.8 61.57 Tnc* $A_{55}^{-}P2430472$ Death inducer-obliterator 1 23856 $4.6E-03$ -3.4 40.32							
Ctnna2*A_55_P2075726Catenin (cadherin-associated protein), α 2123862.6E-03-3.652.78Eme1A_51_P401263Essential meiotic endonuclease 1 homolog 1 (Schizosaccharomyces pombe)2684652.6E-03-7.624.19ErmapA_51_P391716Erythroblast membrane-associated protein270282.7E-03-7.740.32Robo1A_55_P1985070 Sox9Roundabout homolog 1 (Drosophila) Sox9198763.5E-03-3.024.19Sox9A_52_P214630 SRY-box containing gene 9206824.4E-03-6.861.57Tnc*A_55_P2430472Death inducer-obliterator 1238564.6E-03-3.440.32							
Eme1 A_51_P401263 Essential meiotic endonuclease 1 homolog 1 (Schizosaccharomyces pombe) 268465 2.6E-03 -7.6 24.19 Ermap A_51_P391716 Erythroblast membrane-associated protein 27028 2.7E-03 -7.7 40.32 Robo1 A_55_P1985070 Roundabout homolog 1 (Drosophila) 19876 3.5E-03 -3.0 24.19 Sox9 A_52_P214630 SRY-box containing gene 9 20682 4.4E-03 -6.8 61.57 Tnc* A_55_P2430472 Death inducer-obliterator 1 23856 4.6E-03 -3.4 40.32			Catenin (cadherin-associated				
Ermap A_51_P391716 Erythroblast membrane-associated protein 27028 2.7E-03 -7.7 40.32 Robo1 A_55_P1985070 Roundabout homolog 1 (<i>Drosophila</i>) 19876 3.5E-03 -3.0 24.19 Sox9 A_52_P214630 SRY-box containing gene 9 20682 4.4E-03 -6.8 61.57 Tnc* A_52_P355169 Tenascin C 21923 4.6E-03 -54.3 52.78 Dido1 A_55_P2430472 Death inducer-obliterator 1 23856 4.6E-03 -3.4 40.32	Eme1	A_51_P401263	Essential meiotic endonuclease 1 homolog 1 (Schizosaccharomyces	268465	2.6E-03	-7.6	24.19
Robo1 A_55_P1985070 Roundabout homolog 1 (<i>Drosophila</i>) 19876 3.5E-03 -3.0 24.19 Sox9 A_52_P214630 SRY-box containing gene 9 20682 4.4E-03 -6.8 61.57 Tnc* A_52_P355169 Tenascin C 21923 4.6E-03 -54.3 52.78 Dido1 A_55_P2430472 Death inducer-obliterator 1 23856 4.6E-03 -3.4 40.32	Ermap	A_51_P391716	Erythroblast membrane-associated	27028	2.7E-03	-7.7	40.32
Sox9 A_52_P214630 SRY-box containing gene 9 20682 4.4E-03 -6.8 61.57 Tnc* A_52_P355169 Tenascin C 21923 4.6E-03 -54.3 52.78 Dido1 A_55_P2430472 Death inducer-obliterator 1 23856 4.6E-03 -3.4 40.32	Robo1	A 55 P1985070		19876	3.5E-03	-3.0	24,19
Tnc* A_52_P355169 Tenascin C 21923 4.6E-03 -54.3 52.78 Dido1 A_55_P2430472 Death inducer-obliterator 1 23856 4.6E-03 -3.4 40.32							
Dido1 A_55_P2430472 Death inducer-obliterator 1 23856 4.6E-03 -3.4 40.32							
			Catenin (cadherin-associated				
protein), α 2	1000 100 50 15"			000 · = ·			
4833423E24Rik A_66_P106783 RIKEN cDNA 4833423E24 gene 228151 5.2E-03 -8.3 6.82							
Tmsb10*A_55_P2168990Thymosin, $β$ 10192407.3E-03-2.49.86Tmsb10*A_55_P00000055Thymasia 0.10100400.65_000.00							
Tmsb10*A_55_P2092085Thymosin, β 10192408.6E-03-2.39.86		A_55_P2092085		19240	8.6E-03	-2.3	9.86

Definition of abbreviations: dCMP, deoxycytidine monophosphate; PDZ, post-synaptic density protein, Drosophila disc large tumor suppressor, and zonula occludens-1 protein; SRY, sex determining region Y.

*Genes with methylation in more than one locus.

Table 3. Genes with Differential DNA Methylation as well as Differential Messenger RNA Expression in Bronchopulmonary Dysplasia Lung Compared with Preterm Lung, Arranged in Order of Decreasing Fold Change

Gene Symbol	Probeset ID	Gene Title	Entrez Gene	Adjusted P Value	Fold Change in Gene Expression	Location	% Me Preterm	% Me Term	% Me BPD
GFI1	206589_at	Growth factor independent 1	2672	4.34E-02	1.87	cg01766941; chr1: 92945907-	0.57	0.69	0.69
ANKRD55 TP53RK NRP2* NRP2*	220112_at 225402_at 223510_at 223510_at	Ankyrin repeat domain 55 TP53 regulating kinase Neuropilin 2 Neuropilin 2	79722 112858 8828 8828	4.90E-02 3.63E-02 3.85E-02 3.85E-02	1.32 1.39 1.32 1.32	eg22709202 cg22709202 cg10307632 cg19795793; chr2:	0.58 0.24 0.87 0.54	0.62 0.38 0.91 0.73	0.66 0.37 0.91 0.73
CDH23 ZNF438 TRPS1*	232845_at 1563333_at 224218_s_at	Cadherin-like 23 Zinc finger protein 438 Trichorhinophalangeal	64072 220929 7227	1.98E-02 3.49E-02 4.03E-02	1.30 1.27 1.21	206549599–206551316 cg15077792 cg01656216 cg06368590; chr8:	0.07 0.71 0.06	0.13 0.57 0.15	0.15 0.58 0.16
TRPS1*	224218_s_at	syndrome I Trichorhinophalangeal	7227	4.03E-02	1.21	116679698–116679936 cg16821992; chr8: 116670608_116670036	0.12	0.27	0.27
TRPS1*	224218_s_at	Trichorhinophalangeal	7227	4.03E-02	1.21	cg12396523; chr8:	0.07	0.13	0.11
MYBPC1	214087_s_at	Myosin binding protein C, slow type	4604	6.98E-03	1.14	cg21726618; cg21726618; chr12:102036253-	0.32	0.41	0.42
PRDM16	237965_at	PR domain containing 16	63976	2.10E-02	1.11	102030461 cg17033287; chr1:	0.22	0.33	0.33
PHC1	225958_at	Polyhomeotic homolog 1	1911	2.78E-02	0.91	3056541-3056772 cg09912793; chr12:	0.16	0.25	0.23
RYBP	201845_s_at	RING1 and YY1 binding	23429	2.56E-02	0.89	9000340-900/400 cg16990174; chr3: 7040555	0.20	0.28	0.28
BAIAP2 [†]	207832_at	protein BAI1-associated protein 2	10458	3.96E-02	0.87	r z493833-r z49883z cg00026327; chr17: 70051903 2005253	0.72	0.58	0.59
KIAA1217 [†] CASZ1	1560115_a_at 233863_at	KIAA1217 Castor homolog 1, zinc	56243 54897	2.47E-02 3.57E-02	0.85 0.81	r 903 1092–1 9032334 cg26229043 cg10234511	0.12 0.40	0.21 0.56	0.20 0.61
ACHE	205377_s_at	Tinger (<i>Urosophila</i>) Acetylcholinesterase (Yt	43	2.72E-02	0.79	cg10611760; chr7:	0.79	0.89	0.89
BAIAP2 [†]	1556145_a_at	biood group) BAI1-associated protein 2	10458	2.53E-03	0.79	100492217-100494941 cg00026327; chr17: 70051900 70050501	0.72	0.58	0.59
KCNH2	205262_at	Potassium voltage-gated channel, subfamily H	3757	3.50E-02	0.79	r 903 1092-19032334 cg24830730; chr7; 150655108-150655643	0.15	0.33	0.31
STXBP6	230560_at	(eag-related), member 2 Syntaxin binding protein 6	29091	4.57E-02	0.77	cg11775837; 	0.07	0.11	0.11
BTC	207326_at	(armsyn) Betacellulin	685	1.68E-02	0.74	crir 14:2001 0424-200 190 12 cg09346617; chr4: 7574024 55740240	0.08	0.11	0.12
FLJ22536	229280_s_at	Hypothetical locus	401237	4.77E-02	0.72	cg03854238	0.14	0.25	0.25
EHD4 [†]	1556607_at	EH-domain containing 4	30844	4.23E-02	0.72	cg21824733; chr15: 42102012, 42102255	0.22	0.29	0.28
EHD4 [†]	1556608_a_at	EH-domain containing 4	30844	3.63E-02	0.71	42192913-42193255 42192913-42193255	0.22	0.29	0.28
								Q	(Continued)

ORIGINAL RESEARCH

	(
Gene Symbol	Probeset ID	Gene Title	Entrez Gene	Adjusted P Value	Fold Change in Gene Expression	Location	% Me Preterm	% Me Term	% Me BPD
MYOM2	205826_at	Myomesin (M-protein) 2, 165 kD/myomesin (M-protein) 2,	9172	2.36E-03	0.70	cg05241134	0.18	0.28	0.25
PLEKHB1*	209504_s_at		58473	4.32E-02	0.70	cg26776957	0.21	0.36	0.35
PLEKHB1*	209504_s_at	(evectins) member 1 Pleckstrin homology domain containing, family	58473	4.32E-02	0.70	cg25288155	0.27	0.36	0.36
KCNC3	230531_at	B (evectins) member 1 Potassium voltage-gated channel, Shaw-related	3748	2.96E-02	0.70	cg00740020; chr19: 50833813-50834128	0.10	0.16	0.13
NRG2	208062_s_at	subtamily, member 3 Neuregulin 2	9542	2.05E-02	0.70	cg19583819; chr5:	0.27	0.41	0.41
C13orf26*	243884_at	Chromosome 13 open	122046	2.91E-02	0.70	139283300-139284282 cg13614409	0.07	0.14	0.14
C13orf26*	243884_at	reaging trame 20 Chromosome 13 open	122046	2.91E-02	0.70	cg00424169	0.22	0.36	0.36
EYA4	207327_at	Eyes absent homolog 4	2070	4.06E-02	0.69	cg08917489; chr6:	0.21	0.27	0.27
Kiaa1217 [†] NBEA	244147_at 226439_s_at	KIAA1217 Neurobeachin	56243 26960	4.02E-02 1.19E-02	0.69 0.68	133302000-133303300 cg26229043 cg21392700; chr13:	0.12 0.24	0.21 0.32	0.20 0.31
KIAA1217 [†] NCALD	232762_at 1556952_at	KIAA1217 Neurocalcin delta	56243 83988	1.34E-02 5.39E-04	0.67 0.67	300495/0-36030139 cg26229043 cg00680551; chr8:	0.12 0.08	0.21 0.17	0.20 0.17
GSTM3	235867_at	Glutathione S-transferase	2947	1.70E-02	0.66	105133914-105130775 cg10807101; chr1: 110080551 11008206	0.22	0.36	0.40
ADCY1	213245_at	Adenylate cyclase 1 (brain)	107	4.40E-02	0.62	110202331-110203300 cg08619378; chr7: 76613386 46616604	0.67	0.75	0.75
DSCAML1*	232059_at	Down syndrome cell adhesion	57453	4.87E-02	0.62	43013360-43013304 cg05223210	0.50	0.62	0.62
DSCAML1*	232059_at	Down syndrome cell	57453	4.87E-02	0.62	cg11776727	0.62	0.76	0.77
DSCAML1*	232059_at	adresion molecule like I Down syndrome cell adhesion	57453	4.87E-02	0.62	cg07533617	0.84	0.92	0.93
BMP7	209590_at	notecute like 1 Bone morphogenetic protein 7 (osteogenic protein 1)	655	3.48E-02	0.53	cg11598935; chr20; 55839287–55839766	0.48	0.63	0.68
Definition of ab	phreviations: BAI1.	Definition of abbreviations: BAI1 brain-specific andiogenesis inhibitor 1: BPD bronchool Imponery dysolasia: EH Eps 15 homoloov: Me methylation: PB positive regulatory: BING Beally	1: BPD, hrc	Inchonuluona	rv dvsplasia: FH, Fps1	5 homoloov: Me methylation: PB p	ositive realits	atony. RINC	

Definition of abbreviations: BA11, brain-specific angiogenesis inhibitor 1; BPD, bronchopulmonary dysplasia; EH, Eps15 homology; Me, methylation; PR, positive regulatory; RING, Really Interesting New Gene; TP53, tumor protein 53; Yt, Cartwright; YY1, Yin yang 1. % Me indicates methylation level of CpG locus. *Genes with methylation in more than one locus. †Genes with differential expression identified by multiple probe sets.

Cuna, Halloran, Faye-Petersen, et al.: DNA Methylation in Lung Development

Table 3. (Continued)

ORIGINAL RESEARCH

Table 4. Genes with Decreased DNA Methylation and Increased Messenger RNA Expression in Bronchopulmonary Dysplasia Lung

 Compared with Preterm Lung

Gene Symbol	Probe Name	Gene Title	Entrez Gene	Adjusted <i>P</i> Value	Fold Change	Location	% Me Preterm	% Me Term	% Me BPD	Location of CpG Site
ZNF438	1563333_at	Zinc finger protein 438	220929	3.49E-02	1.27	cg01656216	0.71	0.57	0.58	Enhancer

Definition of abbreviations: BPD, bronchopulmonary dysplasia; CpG, cytosine-phosphateguanine dinucleotide; Me, methylation. % Me indicates methylation level of CpG locus.

those from term lung. A total of 437 genes located in 483 loci were identified that were differentially methylated between preterm and term lung. Of these, 33 genes had increased methylation in preterm compared with term lung (Table E11), and 402 genes had increased methylation in term compared with preterm lung (Table E12 showing top 50 out of 402 genes). Two genes, myomesin 2 and copine family member IX, were methylated in two loci, with one locus having increased methylation in preterm lung and the other locus having increased methylation in term lung. A total of 34 other genes had methylation in more than one locus, all of which had increased methylation in term lung (Table E13).

Overlap of Mouse and Human Methylation Data

Methylation data obtained from murine lung tissue (adult versus newborn) were overlapped with methylation data obtained from control human lung (term versus preterm) to identify genes with conserved methylation across the two species during alveolar septation. Twenty genes were identified that were differentially methylated in adult versus newborn mouse lung and also differentially methylated in term versus preterm human lung (Table 7; Figure 1; P < 0.001). Evaluation of overlap at the pathway level using IPA identified (at P <0.05) 16 pathways differentially methylated in mouse lung, and seven differentially methylated in human lung (Table E14). Three pathways were common to both mouse and human lung DNA methylation analyses (basal cell carcinoma signaling, axonal guidance signaling, sonic hedgehog signaling; Table E14).

Discussion

In this study we integrated genome-wide DNA methylation and gene expression data

from murine and human lung tissue samples to identify genes that are possibly regulated by DNA methylation during normal and abnormal alveolar septation. The concept that DNA methylation plays an important role in development is not new. Initial studies done in mice have demonstrated elegantly that, when genes encoding for DNA methyltransferases were silenced or overexpressed, affected mice developed abnormally and died in utero (19, 20). Other studies have shown that development follows a specific pattern of demethylation and remethylation (21), and that deviation from this normal methylation pattern results in abnormal development and increased fetal loss (22). Another study looked at differences in tissue-specific DNA methylation regions between fetal and adult lung tissues, and demonstrated that only 17% of tissuespecific DNA methylation regions present in the fetus were actually conserved into adulthood (23). These and numerous other studies provide evidence that extensive reprogramming of the epigenome by DNA methylation is important for normal development to occur. Our study extends these previous studies by demonstrating lung-specific alterations in DNA methylation in both murine and human samples, and identifying downstream genes that are potentially involved in lung development.

By comparing methylation and expression data from newborn and adult mouse lung tissue samples, we were able to identify 95 genes involved in normal alveolar septation that were also likely regulated by DNA methylation. These included genes involved with the immune system, antioxidant defense, extracellular matrix (ECM) formation, and lung cancer. Genes previously reported in other studies to be important in lung development (WNT1 inducible signaling pathway protein 2 [24],WNT inhibitory factor 1 [25], angiopoietin 2 [26], and sex-determining region Y-box 9 [27]) were also observed in our study, further validating their importance, as well as offering insight into the role DNA methylation may have in regulating their expression. A number of genes with less obvious significance to alveolar septation were also noted, and further evaluation of these targets is required to determine their role in septation.

We identified 13 genes known to function in inflammation and immune system response (chitinase-like 3 [Chi3l3], B-cell CLL/lymphoma 6 [Bcl6], chemokine [C-C motif] receptor 6 [Ccr6], signal transducer and activator of transcription 4 [Stat4], Ccl5, CD209a antigen [Cd209a], histocompatibility 2, O region B locus [H2-Ob], CD19 antigen [Cd19], SH2 domain containing 1A [Sh2 d1a], killer cell lectinlike receptor subfamily B member 1B [Klrb1b], B cell linker [Blnk], β-2 microglobulin [B2 m], and protein kinase C, θ [Prkcq]), the expression of which were decreased in newborn and increased in adult lung. Similar changes in inflammatory/immune system genes were also observed by Cortese and colleagues (28) in lung development and cancer. A similar pattern of regulation was also seen in superoxide dismutase 3, extracellular (Sod3) and peroxiredoxin 6 (Prdx6) expression, genes known to have important antioxidant activity in the lungs (29). Increased expression of genes involved in immune and antioxidant defense correlates with the expected exposure of the newborn lungs to numerous environmental stressors soon after birth. Possible regulation of these genes by methylation offers an interesting target for augmenting immune and antioxidant defense in the lungs, especially for premature infants who are at higher risk for developing oxidant-induced lung injury.

Genes involved in ECM formation and organization, such as elastin (Eln), tenascin C (Tnc), collagen (Col), type VI,

ORIGINAL RESEARCH

ger RNA Expression in Bronchopulmonary Dysplasia Lung Compared with Preterm Lung,		
Table 5. Genes with Increased DNA Methylation and Decreased Messe	Arranged in Order of Decreasing Fold Change	

Gene	Probe	Gene	Entrez	Adjusted	Fold	-	% Me	% Me	% Me	Location of
odmyc	Name	litte	Gene	P value	cnange	Location	Preterm	lerm	рчр	CpG Site
PHC1	225958_at	Polyhomeotic homolog 1	1911	2.78E-02	0.91	cg09912793; chr12: 0066046_0067480	0.16	0.25	0.23	N_Shore
RYBP	201845_s_at	RING1 and YY1 binding	23429	2.56E-02	0.89	cg16990174; chr3: 77405652 77406850	0.20	0.28	0.28	S_Shore
KIAA1217* CASZ1	1560115_a_at 233863_at	Protein KIAA1217 Castor homolog 1, zinc	56243 54897	2.47E-02 3.57E-02	0.85 0.81	/ z49063 <i>5-1</i> z49063z cg26229043 cg10234511	0.12 0.40	0.21 0.56	0.20 0.61	Enhancer Enhancer
ACHE	205377_s_at	Tinger (Urosopnia) Acetylcholinesterase	43	2.72E-02	0.79	cg10611760; chr7:	0.79	0.89	0.89	N_Shore
KCNH2	205262_at	(11 blood group) Potassium voltage-gated channel, subfamily H	3757	3.50E-02	0.79	100492217-10494941 cg24830730; chr7: 150655108-150655643	0.15	0.33	0.31	N_Shore
STXBP6	230560_at	(eag-related), member 2 Syntaxin binding protein 6	29091	4.57E-02	0.77	cg11775837; chr14:	0.07	0.11	0.11	Island
BTC	207326_at	armsyry Betacellulin	685	1.68E-02	0.74	23310424-23319012 cg09346617; chr4: 75710101 75710710	0.08	0.11	0.12	Island
FLJ22536 EHD4*	229280_s_at 1556607_at	Hypothetical locus LOC401237 EH-domain containing 4	401237 30844	4.77E-02 4.23E-02	0.72 0.72	73713101-73713740 cg03854233 cg21824733; chr15:	0.14 0.22	0.25 0.29	0.25 0.28	Enhancer S_Shelf
EHD4*	1556608_a_at	EH-domain containing 4	30844	3.63E-02	0.71	42192913-42195233 cg21824733; chr15: 42102013 42102555	0.22	0.29	0.28	S_Shelf
MYOM2	205826_at	Myomesin (M-protein) 2, 165 kD/myomesin Macrotoin 2, 165 kD	9172	2.36E-03	0.70	42132313-42133233 cg05241134	0.18	0.28	0.25	Enhancer
PLEKHB1	209504_s_at		58473	4.32E-02	0.70	cg25288155	0.27	0.36	0.36	Body
KCNC3	230531_at	Potassium voltage-gated channel, Shaw-related	3748	2.96E-02	0.70	cg00740020; chr19: 50833813–50834128	0.10	0.16	0.13	N_Shore
NRG2	208062_s_at	Neuregulin 2	9542	2.05E-02	0.70	cg19583819; chr5:	0.27	0.41	0.41	N_Shore
C13orf26	243884_at	Chromosome 13 open	122046	2.91E-02	0.70	1332033300-133204202 cg00424169	0.22	0.36	0.36	Body
EYA4	207327_at	Eyes absent homolog 4	2070	4.06E-02	0.69	cg08917489; chr6: 133650086-133663686	0.21	0.27	0.27	S_Shore
KIAA1217* NBEA	244147_at 226439_s_at	KIAA1217 Neurobeachin	56243 26960	4.02E-02 1.19E-02	0.69 0.68	155290400-15559590 cg26229043 cg21392700; chr13:	0.12 0.24	0.21 0.32	0.20 0.31	Enhancer N_Shore
KIAA1217* NCALD	232762_at 1556952_at	KIAA1217 Neurocalcin delta	56243 83988	1.34E-02 5.39E-04	0.67 0.67	5004937.0-50030139 cg26229043 cg00880551; chr8:	0.12 0.08	0.21 0.17	0.20 0.17	Enhancer N_Shore
GSTM3	235867_at	Glutathione S-transferase	2947	1.70E-02	0.66	cg10807101; chr1: cg10807101; chr1: 110000261 11000206	0.22	0.36	0.40	N_Shore
ADCY1	213245_at	Adenylate cyclase 1 (brain)	107	4.40E-02	0.62	008619378; chr7: cg08619378; chr7: 76613386_76616504	0.67	0.75	0.75	S_Shore
DSCAML1 [†]	232059_at	Down syndrome cell adhesion molecule like 1	57453	4.87E-02	0.62	cg05223210	0.50	0.62	0.62	Enchancer

(Continued)

ontinu
5
+
~
~
0
~~~
()
-
<u> </u>
<u>ن</u>
ي. ن
le 5.
able

ed)

Gene Symbol	Probe Name	Gene Title	Entrez Gene	Adjusted P value	Fold change	Location	% Me Preterm	% Me Term	% Me BPD	% Me Location of BPD CpG Site
DSCAML1 [†]	232059_at	Down syndrome cell	57453	4.87E-02	0.62	cg11776727	0.62	0.76	0.77	Enchancer
DSCAML1 [†]	232059_at	adriesion molecule like I Down syndrome cell	57453	4.87E-02	0.62	cg07533617	0.84	0.92	0.93	Enchancer
BMP7	209590_at	adriesion morecule like 1 Bone morphogenetic protein 7 (osteogenic protein 1)	655	3.48E-02	0.53	cg11598935; chr20: 55839287–55839766	0.48	0.63	0.68	0.68 N_Shore
Definition of ab	breviations: BPD, I	Definition of abbreviations: BPD, bronchopulmonary dysplasia; CpG, cytosine-guanine dinucleotide; Eag, ether-a-go-go; EH, Eps15 homology; Me, methylation; RING, Really Interesting New	osine-guan	ine dinucleotid	le; Eag, eth€	ar-a-go-go; EH, Eps15 homoloç	gy; Me, methy	lation; RIN	IG, Really	Interesting New

expression identified by multiple probe sets.

*Genes with differential expression identified by n  † Genes with methylation in more than one locus. % Me indicates methylation level of CpG locus.

Yt, Cartwright; YY1, Yin yang

Gene;

 $\alpha$  3 (Col6a3), and Col, type XXVII,  $\alpha$  1 (Col27a1), were observed to have increased expression and decreased methylation in the newborn, with subsequent decreased expression and increased methylation in the adult. Such an expression profile is consistent with the rapid and marked increase in ECM seen during alveolar septation (13, 28); similar increases in ECM-related genes were also observed by Cortese and colleagues (28). Three genes (S-phase kinase-associated protein 2 [Skp2], ribonucleotide reductase M [Rrm] 1, and Rrm2) were identified, the increased expression of which is typically associated with various forms of lung cancer in adults (30-32). In our study, these genes were shown to have increased expression only in newborns, with subsequent decreased expression in adults. It has been hypothesized that dysregulation of genes involved in normal development may play an important role in carcinogenesis (33). Our study suggests that Skp2, Rrm1, and Rrm2 are normally expressed during alveolar septation in the newborn, but repressed upon alveolar maturation in the adult. It is speculated that abnormal reexpression of these genes in adult lung (a recapitulation of development) may contribute to the pathogenesis of lung cancer. We compared methylation and expression data from human lung tissue samples to identify genes involved in

abnormal alveolar septation seen in BPD. A total of 23 genes were identified that exhibited inverse correlation between methylation and expression, suggesting regulation by DNA methylation. A select number of these 23 genes are of particular interest. Glutathione S-transferase M3 (Gtsm3) is a detoxifying enzyme that metabolizes oxidative compounds from exposure to environmental toxins. Studies have shown that genetic variations of this gene are associated with poor lung growth and function in relation to environmental toxin exposure (34), and correlated with severity of lung diseases, such as cystic fibrosis (35). Betacellulin is an epidermal growth factor, the overexpression of which in mice resulted in severe pulmonary pathology, including thickening of alveolar septa, intra-alveolar accumulation of hemosiderin-containing macrophages, and nodular pulmonary remodeling-features commonly seen in BPD (36). Finally, bone morphogenetic protein (Bmp) 7 is

a member of the transforming growth factor (TGF)- $\beta$  superfamily that has been reported to oppose the activity of TGF- $\beta$  in lungs (37). As increased TGF- $\beta$  signaling in the lung results in pulmonary fibrosis and arrested lung development (38), Bmp7, as an endogenous antagonist for TGF- $\beta$ , may be an interesting target for therapy in BPD.

We also compared methylation patterns of preterm versus term human lung with newborn versus adult mouse lung, and identified 20 genes with shared differential methylation in both human and mouse lung. Of these, six genes (Shisa3, Nrn1, Ext1, Gria1, E2f8, and Robo1) were identified in our study as potentially regulating gene expression. The relevance of the remaining 14 genes with shared methylation patterns between mouse and human lungs is unknown at present, and needs further study. It is possible that these genes with methylation differences during development, but without corresponding changes in gene expression, have other regulators of gene transcription (e.g., microRNA, transcription factors) that overrule or modify the effects of changes in DNA methylation. We also identified three pathways (basal cell carcinoma signaling, axonal guidance signaling, and sonic hedgehog signaling) that were common to both mouse and human lung DNA methylation analyses. Of these pathways, basal cell carcinoma signaling pathway represents constitutive activation of sonic hedgehog signaling. Molecules involved in sonic hedgehog signaling (e.g., sonic hedgehog homolog, patched, gliotactin) (39, 40) and axonal guidance (e.g., Netrins, Slits, and Robo receptors, Semaphorins, Ephrins) (41-45) are well known to be involved in lung development, and our results suggest that DNA methylation may help regulate them.

Our study focused on genes that showed an inverse relationship between methylation and expression, as this reflects the current mainstream understanding that DNA methylation of CpG sites located near promoter regions is associated with inhibition of gene expression. There is, however, increasing evidence that the function of DNA methylation in regulating gene expression may vary, depending upon the precise location and context of the CpG sites relative to the gene in question (i.e., gene body versus the shores, shelves, and enhancers surrounding the promoter CpG islands) (46), and that methylation

 Table 6.
 Pathways Associated with Genes Both Differentially Methylated and

 Expressed in Bronchopulmonary Dysplasia Lung Compared with Preterm Lung

Canonical Pathways	-log(P Value)	Ratio	Molecules
ErbB signaling Neuregulin signaling RhoA signaling Cellular effects of sildenafil (Viagra) Cardiomyocyte differentiation via BMP receptors	2.05E-00 2.03E-00 1.79E-00 1.71E-00 1.5E-00	1.92E-02 1.64E-02	NRG2, BTC NRG2, BTC NRP2, BAIAP2 ADCY1, KCNH2 BMP7
Axonal guidance signaling Glutathione-mediated detoxification	1.47E-00 1.34E-00	6.21E-03 2.27E-02	NRP2, BAIAP2, BMP7 GSTM3

Definition of abbreviations: ADCY1, adenylate cyclase 1; BAIAP2, brain-specific angiogenesis inhibitor 1-associated protein 2; BMP, bone morphogenetic protein; BTC, betacellulin; ErbB, erbB receptor tyrosine kinase; GSTM3, glutathione S-transferase  $\mu$  3; KCNH2, potassium voltage-gated channel, subfamily H, member 2; NRG2, neuregulin 2; NRP2, neuropilin 2; RhoA, ras homolog gene family, member A.

and expression changes in the same direction may also be important. In light of this, we have also characterized and reported on genes with a direct correlation between methylation and expression, and have specified the location of the differentially methylated CpG sites in relation to the gene. These data may be helpful as we gain a better understanding of how methylation of specific CpG sites regulates gene expression.

Our study provides valuable insights into many aspects of normal and damaged lung development, but several inherent limiting factors warrant discussion. Although we have shown an inverse correlation between DNA methylation and gene expression for a number of genes involved in normal and abnormal alveolar septation, we cannot conclude that the changes in expression of these genes occurred solely because of changes in DNA methylation. To prove that the DNA methylation changes we identified drive the changes in gene expression, mechanistic studies that target these genes and their regulation by DNA methylation using in vivo models would be required. Our study was also conducted on whole lung tissue, containing DNA and RNA from multiple cell types and compartments. This could have resulted in contamination of results due to inclusion of cells that do not directly participate in alveolar septation. The magnitude of observed changes in DNA methylation may be lower due to the mixture of cells in the whole lung, as actual changes may be cell-type specific. Further studies, possibly using laser capture microdissection or cell sorting to isolate developing secondary septa, are needed

Table 7. Common Genes Differentially Methylated in Mouse Newborn versus Adult Lung and Human Preterm versus Term Lung

Gene Symbol	Gene Title	% Methylation Preterm	% Methylation Term	P Value	Methylation in Mouse Newborn versus Adult Lung	P Value
DNMT3A	DNA methyltransferase 3A	0.16	0.27	1.99E-05	Decreased	2.51E-03
SHISA3	Shisa family member 3	0.08	0.14	2.20E-05	Decreased	1.44E-03
KCNMA1	Potassium large conductance calcium-activated channel, subfamily Μ, α member 1	0.32	0.43	4.36E-05	Decreased	3.67E-04
NRN1	Neuritin 1	0.10	0.13	6.18E-05	Decreased	1.69E-07
WDFY4	WDFY family member 4	0.16	0.28	6.71E-05	Decreased	2.43E-03
CASZ1	Castor zinc finger 1	0.40	0.56	1.41E-04	Decreased	4.32E-03
PITPNC1	Phosphatidylinositol transfer protein, cytoplasmic 1	0.14	0.21	1.42E-04	Decreased	7.76E-03
EXT1	Exostosinglycosyltransferase 1	0.08	0.22	1.57E-04	Decreased	5.83E-04
UBE2E2	Ubiquitin-conjugating enzyme E2E 2	0.27	0.37	2.85E-04	Decreased	8.76E-04
GRIA1	Glutamate receptor, ionotropic, AMPA 1	0.10	0.17	2.93E-04	Decreased	7.84E-04
TBX4	T-box 4	0.16	0.21	3.42E-04	Decreased	2.65E-03
ADAMTSL2	ADAMTS-like 2	0.09	0.22	3.53E-04	Decreased	1.65E-03
E2F8	E2F transcription factor 8	0.11	0.15	3.63E-04	Decreased	3.30E-05
PRDM8	PR domain containing 8	0.23	0.35	4.21E-04	Decreased	1.23E-03
ROBO1	Roundabout homolog 1	0.08	0.10	4.35E-04	Decreased	3.55E-03
IFNAR2	interferon ( $\alpha$ , $\beta$ and $\omega$ ) receptor 2	0.07	0.11	4.89E-04	Decreased	2.88E-04
PRICKLE1	Prickle homolog 1	0.11	0.18	6.37E-04	Decreased	1.23E-05
BMPER	BMP-binding endothelial regulator	0.07	0.11	8.51E-04	Decreased	5.96E-04
CTNNA2	Catenin (cadherin associated protein)	0.18	0.30	9.08E-04	Decreased	2.61E-03
AUTS2	Autism susceptibility candidate 2	0.23	0.36	9.38E-04	Decreased	5.66E-05

Definition of abbreviations: ADAMTS, a disintegrin-like and metallopeptidase with thrombospondin; AMPA, α-amino-3-hydroxy-5-methyl-4isoxazolepropionic acid; BMP, bone morphogenetic protein; PR, positive regulatory.

All genes had reduced methylation in human preterm lung and mouse newborn lung as compared with human term or mouse adult lung, respectively.

for validation. Such studies would avoid contamination by gene expression and DNA methylation signals from other regions of the lung. Our study also did not investigate other known epigenetic regulators of gene expression, such as histone acetylation and microRNA. An increasing number of studies have shown that, in addition to DNA methylation, alterations in histone acetylation (47) and microRNA (17) are also important in lung development and disease. The present study had a limited number of human samples, which limits the power of the study. In addition, a limitation is that human gene expression was from a different set of samples from that used for assessment of methylation, although our validation studies show similar patterns of gene expression of selected genes in both samples.

Nevertheless, our study has several important strengths. The genome-wide approach used to identify candidate genes, as compared with the traditional single-pathway or gene approach, allowed unbiased validation of genes previously identified from other studies as important, and enabled identification of novel candidate genes for future research. This integration of gene expression data with DNA methylation data provides additional insight into epigenetic mechanisms regulating observed changes in gene expression. Our evaluation of genes with an inverse relationship between methylation and expression highlights key genes, the expression of which is likely regulated by DNA methylation; this process potentially could enable future studies that manipulate methylation to

influence gene expression. The use of human BPD and preterm and term control lung tissue samples allowed the development of a unique and valuable data set not possible from murine or other animal models of BPD.

Further studies are required to validate candidate genes using mechanistic *in vitro* and subsequent *in vivo* animal studies. Overall, understanding how DNA methylation regulates gene expression during normal alveolar formation may not only yield new insights into normal lung development, but may also provide insights into how dysregulation of DNA methylation contributes to lung disorders.

<u>Author disclosures</u> are available with the text of this article at www.atsjournals.org.

#### References

- 1. Morrisey EE, Hogan BL. Preparing for the first breath: genetic and cellular mechanisms in lung development. *Dev Cell* 2010;18:8–23.
- Coalson JJ. Pathology of bronchopulmonary dysplasia. Semin Perinatol 2006;30:179–184.
- Hagood JS, Ambalavanan N. Systems biology of lung development and regeneration: current knowledge and recommendations for future research. Wiley Interdiscip Rev Syst Biol Med 2013;5:125–133.
- Mariani TJ, Reed JJ, Shapiro SD. Expression profiling of the developing mouse lung: insights into the establishment of the extracellular matrix. *Am J Respir Cell Mol Biol* 2002;26:541–548.
- Kho AT, Bhattacharya S, Tantisira KG, Carey VJ, Gaedigk R, Leeder JS, Kohane IS, Weiss ST, Mariani TJ. Transcriptomic analysis of human lung development. *Am J Respir Crit Care Med* 2010;181: 54–63.
- Bhattacharya S, Go D, Krenitsky DL, Huyck HL, Solleti SK, Lunger VA, Metlay L, Srisuma S, Wert SE, Mariani TJ, *et al.* Genome-wide transcriptional profiling reveals connective tissue mast cell accumulation in bronchopulmonary dysplasia. *Am J Respir Crit Care Med* 2012;186:349–358.
- Jaenisch R, Bird A. Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. *Nat Genet* 2003;33:245–254.
- 8. Smith ZD, Meissner A. DNA methylation: roles in mammalian development. *Nat Rev Genet* 2013;14:204–220.
- Lister R, Mukamel EA, Nery JR, Urich M, Puddifoot CA, Johnson ND, Lucero J, Huang Y, Dwork AJ, Schultz MD, *et al*. Global epigenomic reconfiguration during mammalian brain development. *Science* 2013; 341:1237905.
- Delgado-Calle J, Sañudo C, Fernández AF, García-Renedo R, Fraga MF, Riancho JA. Role of DNA methylation in the regulation of the RANKL-OPG system in human bone. *Epigenetics* 2012;7: 83–91.
- Keil KP, Altmann HM, Mehta V, Abler LL, Elton EA, Vezina CM. Catalog of mRNA expression patterns for DNA methylating and demethylating genes in developing mouse lower urinary tract. *Gene Expr Patterns* 2013;13:413–424.
- Bröske AM, Vockentanz L, Kharazi S, Huska MR, Mancini E, Scheller M, Kuhl C, Enns A, Prinz M, Jaenisch R, et al. DNA methylation protects hematopoietic stem cell multipotency from myeloerythroid restriction. Nat Genet 2009;41:1207–1215.
- Burri PH. Structural aspects of postnatal lung development—alveolar formation and growth. *Biol Neonate* 2006;89:313–322.

 Mohn F, Weber M, Schübeler D, Roloff TC. Methylated DNA immunoprecipitation (MeDIP). *Methods Mol Biol* 2009;507:55–64.

- Maksimovic J, Gordon L, Oshlack A. SWAN: subset-quantile within array normalization for illumina infinium HumanMethylation450 BeadChips. *Genome Biol* 2012;13:R44.
- Storey JD, Tibshirani R. Statistical significance for genomewide studies. *Proc Natl Acad Sci USA* 2003;100:9440–9445.
- Schulz MH, Pandit KV, Lino Cardenas CL, Ambalavanan N, Kaminski N, Bar-Joseph Z. Reconstructing dynamic microRNA-regulated interaction networks. *Proc Natl Acad Sci USA* 2013;110: 15686–15691.
- Purevdorj E, Zscheppang K, Hoymann HG, Braun A, von Mayersbach D, Brinkhaus MJ, Schmiedl A, Dammann CE. ErbB4 deletion leads to changes in lung function and structure similar to bronchopulmonary dysplasia. *Am J Physiol Lung Cell Mol Physiol* 2008;294:L516–L522.
- Li E, Bestor TH, Jaenisch R. Targeted mutation of the DNA methyltransferase gene results in embryonic lethality. *Cell* 1992;69: 915–926.
- Biniszkiewicz D, Gribnau J, Ramsahoye B, Gaudet F, Eggan K, Humpherys D, Mastrangelo MA, Jun Z, Walter J, Jaenisch R. Dnmt1 overexpression causes genomic hypermethylation, loss of imprinting, and embryonic lethality. *Mol Cell Biol* 2002;22: 2124–2135.
- Monk M, Boubelik M, Lehnert S. Temporal and regional changes in DNA methylation in the embryonic, extraembryonic and germ cell lineages during mouse embryo development. *Development* 1987;99: 371–382.
- Kang YK, Park JS, Koo DB, Choi YH, Kim SU, Lee KK, Han YM. Limited demethylation leaves mosaic-type methylation states in cloned bovine pre-implantation embryos. *EMBO J* 2002;21:1092–1100.
- Yuen RK, Neumann SM, Fok AK, Peñaherrera MS, McFadden DE, Robinson WP, Kobor MS. Extensive epigenetic reprogramming in human somatic tissues between fetus and adult. *Epigenetics Chromatin* 2011;4:7.
- 24. Pongracz JE, Stockley RA. Wnt signalling in lung development and diseases. *Respir Res* 2006;7:15.
- Goss AM, Tian Y, Tsukiyama T, Cohen ED, Zhou D, Lu MM, Yamaguchi TP, Morrisey EE. Wnt2/2b and beta-catenin signaling are necessary and sufficient to specify lung progenitors in the foregut. *Dev Cell* 2009;17:290–298.
- Felcht M, Luck R, Schering A, Seidel P, Srivastava K, Hu J, Bartol A, Kienast Y, Vettel C, Loos EK, *et al.* Angiopoietin-2 differentially regulates angiogenesis through TIE2 and integrin signaling. *J Clin Invest* 2012;122:1991–2005.

- Turcatel G, Rubin N, Menke DB, Martin G, Shi W, Warburton D. Lung mesenchymal expression of Sox9 plays a critical role in tracheal development. *BMC Biol* 2013;11:117.
- Cortese R, Hartmann O, Berlin K, Eckhardt F. Correlative gene expression and DNA methylation profiling in lung development nominate new biomarkers in lung cancer. *Int J Biochem Cell Biol* 2008;40:1494–1508.
- Zelko IN, Mariani TJ, Folz RJ. Superoxide dismutase multigene family: a comparison of the CuZn-SOD (SOD1), Mn-SOD (SOD2), and EC-SOD (SOD3) gene structures, evolution, and expression. *Free Radic Biol Med* 2002;33:337–349.
- Hung WC, Tseng WL, Shiea J, Chang HC. Skp2 overexpression increases the expression of MMP-2 and MMP-9 and invasion of lung cancer cells. *Cancer Lett* 2010;288:156–161.
- Pitterle DM, Kim YC, Jolicoeur EM, Cao Y, O'Briant KC, Bepler G. Lung cancer and the human gene for ribonucleotide reductase subunit M1 (RRM1). *Mamm Genome* 1999;10:916–922.
- 32. Rahman MA, Amin AR, Wang D, Koenig L, Nannapaneni S, Chen Z, Wang Z, Sica G, Deng X, Chen ZG, *et al*. RRM2 regulates Bcl-2 in head and neck and lung cancers: a potential target for cancer therapy. *Clin Cancer Res* 2013;19:3416–3428.
- Bonner AE, Lemon WJ, Devereux TR, Lubet RA, You M. Molecular profiling of mouse lung tumors: association with tumor progression, lung development, and human lung adenocarcinomas. *Oncogene* 2004;23:1166–1176.
- 34. Breton CV, Vora H, Salam MT, Islam T, Wenten M, Gauderman WJ, Van den Berg D, Berhane K, Peters JM, Gilliland FD. Variation in the *GST mu* locus and tobacco smoke exposure as determinants of childhood lung function. *Am J Respir Crit Care Med* 2009;179: 601–607.
- 35. Flamant C, Henrion-Caude A, Boëlle PY, Brémont F, Brouard J, Delaisi B, Duhamel JF, Marguet C, Roussey M, Miesch MC, et al. Glutathione-S-transferase M1, M3, P1 and T1 polymorphisms and severity of lung disease in children with cystic fibrosis. *Pharmacogenetics* 2004;14:295–301.
- 36. Schneider MR, Dahlhoff M, Herbach N, Renner-Mueller I, Dalke C, Puk O, Graw J, Wanke R, Wolf E. Betacellulin overexpression in transgenic mice causes disproportionate growth, pulmonary hemorrhage syndrome, and complex eye pathology. *Endocrinology* 2005;146:5237–5246.

- Izumi N, Mizuguchi S, Inagaki Y, Saika S, Kawada N, Nakajima Y, Inoue K, Suehiro S, Friedman SL, Ikeda K. BMP-7 opposes TGF-beta1-mediated collagen induction in mouse pulmonary myofibroblasts through Id2. *Am J Physiol Lung Cell Mol Physiol* 2006;290:L120–L126.
- Vicencio AG, Lee CG, Cho SJ, Eickelberg O, Chuu Y, Haddad GG, Elias JA. Conditional overexpression of bioactive transforming growth factor-β1 in neonatal mouse lung: a new model for bronchopulmonary dysplasia? *Am J Respir Cell Mol Biol* 2004;31: 650–656.
- 39. Liu L, Kugler MC, Loomis CA, Samdani R, Zhao Z, Chen GJ, Brandt JP, Brownell I, Joyner AL, Rom WN, et al. Hedgehog signaling in neonatal and adult lung. Am J Respir Cell Mol Biol 2013;48: 703–710.
- Zhang M, Wang H, Teng H, Shi J, Zhang Y. Expression of SHH signaling pathway components in the developing human lung. *Histochem Cell Biol* 2010;134:327–335.
- Dalvin S, Anselmo MA, Prodhan P, Komatsuzaki K, Schnitzer JJ, Kinane TB. Expression of Netrin-1 and its two receptors DCC and UNC5H2 in the developing mouse lung. *Gene Expr Patterns* 2003;3:279–283.
- Liu Y, Stein E, Oliver T, Li Y, Brunken WJ, Koch M, Tessier-Lavigne M, Hogan BL. Novel role for netrins in regulating epithelial behavior during lung branching morphogenesis. *Curr Biol* 2004;14:897–905.
- Greenberg JM, Thompson FY, Brooks SK, Shannon JM, Akeson AL. Slit and robo expression in the developing mouse lung. *Dev Dyn* 2004;230:350–360.
- 44. Vadivel A, Alphonse RS, Collins JJ, van Haaften T, O'Reilly M, Eaton F, Thébaud B. The axonal guidance cue semaphorin 3C contributes to alveolar growth and repair. *PLoS One* 2013;8:e67225.
- 45. Vadivel A, van Haaften T, Alphonse RS, Rey-Parra GJ, Ionescu L, Haromy A, Eaton F, Michelakis E, Thébaud B. Critical role of the axonal guidance cue EphrinB2 in lung growth, angiogenesis, and repair. Am J Respir Crit Care Med 2012;185:564–574.
- 46. Jones PA. Functions of DNA methylation: islands, start sites, gene bodies and beyond. *Nat Rev Genet* 2012;13:484–492.
- 47. Nagarajan P, Ge Z, Sirbu B, Doughty C, Agudelo Garcia PA, Schlederer M, Annunziato AT, Cortez D, Kenner L, Parthun MR. Histone acetyl transferase 1 is essential for mammalian development, genome stability, and the processing of newly synthesized histones H3 and H4. *PLoS Genet* 2013;9:e1003518.